Announcement • Jul 21
Citius Oncology Reports Nationwide Deployment of Lymphir's Broadened Commercial Organization and Expanding Market Adoption Citius Oncology, Inc. provided an update on the commercial launch of LYMPHIR® (denileukin diftitox-cxdl), highlighting continued progress across market access, commercial execution, and physician adoption. Citius Oncology has expanded its commercial organization to include 21 additional commercial field-based professionals and added eight medical science liaisons dedicated to supporting complex clinical practitioner engagement and patient care. All personnel are expected to be fully onboarded and deployed nationwide by August 2026. The expansion of the commercial and medical teams was facilitated by the Company's May 2026 financing and implemented by EVERSANA, Citius Oncology's exclusive commercialization partner. EVERSANA also provides Citius Oncology with an integrated suite of operations services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, channel management, and patient assistance. As part of its commercialization strategy, Citius Oncology has also deployed a proprietary artificial intelligence-driven commercial intelligence platform designed to enhance customer engagement, identify treatment opportunities, optimize resource allocation, and support data-driven decision-making across its commercial organization. The Company reports continued expansion in the number of accounts ordering LYMPHIR, reflecting increasing physician familiarity with the product and growing utilization across both academic and community treatment settings. Citius Oncology expects continued growth in orders and patient adoption throughout the remainder of 2026. Breakeven Date Change • May 17 The analyst covering Citius Oncology previously expected the company to break even in 2027. New forecast suggests losses will reduce by 29% to 2026. The company is expected to make a profit of US$43.6m in 2027. Average annual earnings growth of 43% is required to achieve expected profit on schedule.
Announcement • May 07
Citius Oncology, Inc. announced that it expects to receive $36.5 million in funding Citius Oncology, Inc. announced that it will raise $36.5 million in a round of funding from new lenders Avenue Venture Opportunities Fund II, L.P., fund managed by Avenue Capital Group, LLC on May 5, 2026. The company issued credit facility which has a term of 3.5 years and includes an initial tranche of $10 million, to be fully funded at closing, plus two additional tranches of up to an aggregate of $15 million, subject to achievement of predefined revenue milestones and liquidity conditions. The Company has agreed to issue to Avenue warrants to purchase up to 11,111,111 shares of the Company's common stock, at an exercise price of $0.90 per share, exercisable for a period of five years following the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants. The Company will also issue to Avenue warrants to purchase shares of common stock equal to 10% of the amount funded in each future tranche, divided by the exercise price of $0.90 per share. Additionally, Avenue will have the right, at any time while any loan is outstanding, to convert up to $4.0 million of the outstanding principal under the credit facility into shares of the Company's common stock at a price per share equal to 120% of the exercise price of the warrant, subject to certain terms and conditions, including beneficial ownership limitations. 
